Company intelligence / Profile preview
Pephexia Therapeutics
Copenhagen, Denmarkpephexia.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Other
01
Overview
Pephexia Therapeutics develops novel peptide-based drugs targeting cachexia and related muscle-wasting conditions. Their lead candidate PEP‑366 targets cancer cachexia and has received significant grant funding to support progression toward clinical trials. The company has presented promising preclinical data at major scientific conferences but has not yet reported human clinical results as of mid‑2025.
- Therapeutic areas
- Metabolic DisordersPulmonologyOncologyNephrologyImmunologyCardiovascular
- Modalities
- PeptidesPeptide-based pharmacotherapies
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Danish Innovation Fund (via Grand Solution grant)
Beyond the preview
Go deeper on Pephexia Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pephexia Therapeutics.